You have full text access to this OnlineOpen article

Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience

  1. I. D. R. Arnott1,
  2. D. McDonald2,
  3. A. Williams2,
  4. S. Ghosh1

Article first published online: 7 JUL 2008

DOI: 10.1046/j.1365-2036.2001.01092.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 15, Issue 10, pages 1639–1646, October 2001

Additional Information

How to Cite

Arnott, I. D. R., McDonald, D., Williams, A. and Ghosh, S. (2001), Clinical use of Infliximab in Crohn’s disease: the Edinburgh experience. Alimentary Pharmacology & Therapeutics, 15: 1639–1646. doi: 10.1046/j.1365-2036.2001.01092.x

Author Information

  1. 1

    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK

  2. 2

    Department of Gastroenterology, St John’s Hospital at Howden, Livingston, UK

* Dr I. D. R. Arnott, Gastrointestinal Unit, Department of Medical Sciences, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK. E-mail: iarnott@ed.ac.uk

Publication History

  1. Issue published online: 7 JUL 2008
  2. Article first published online: 7 JUL 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (149K)

References

  • 1
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 1029 – 35.
  • 2
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398 – 405.
  • 3
    D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti- tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999; 116: 1029 – 34.
  • 4
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761 – 9.
  • 5
    Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn’s disease: First anniversary clinical experience. Am J Gastroenterol 2000; 95: 3469 – 77.
    Direct Link:
  • 6
    Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 2000; 95: 3490 – 7.
    Direct Link:
  • 7
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722 – 9.
    Direct Link:
  • 8
    Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthr Rheum 1998; 41: 1552 – 63.
    Direct Link:
  • 9
    Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932 – 9.
  • 10
    Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000; 135: 564 – 8.
  • 11
    Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Successful management of Crohn’s disease of the ileoanal pouch with infliximab. Gastroenterology 1999; 117: 429 – 32.
  • 12
    Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthr Rheum 2000; 43: 1346 – 52.
    Direct Link:
  • 13
    Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829 – 30.
  • 14
    Harvey RF & Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980; 1: 514 – 514.
  • 15
    Bayless TM, Tokayer AZ, Polito JMI, Quaskey SA, Mellits ED, Harris ML. Crohn’s disease: Concordance for site and clinical type in affected family members—Potential hereditary influences. Gastroenterology 1996; 111: 573 – 9.
  • 16
    Arnott IR, Shand A, Ghosh S. Administration of infliximab in Crohn’s disease does not deplete complement components C3 and C4. Am J Gastroenterol 2000; 95: 3326 – 7.
    Direct Link:
  • 17
    Schreiber S, Campieri M, Colombel JF, et al. Use of anti-tumour necrosis factor agents in inflammatory bowel disease—European guidelines for 2001–2003. Int J Colorectal Dis 2001; 16: 1 – 11.
  • 18
    Hodgson HJF & Bhatti M. Assessment of disease activity in ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 1995; 1: 117 – 34.
    Direct Link:
  • 19
    Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease index; national cooperative Crohn’s disease study. Gastroenterology 1976; 70: 439 – 44.
  • 20
    Siproudhis L, Mortaji A, Mary JY, Juguet F, Bretagne JF, Gosselin M. Anal lesions: any significant prognosis in Crohn’s disease? Eur J Gastroenterol Hepatol 1997; 9: 239 – 43.
  • 21
    Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83 – 8.
    Direct Link:
  • 22
    Patel RT, Bain I, Youngs D, Keighley MRB. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum 1995; 38: 831 – 7.
  • 23
    Godkin A & Jewell D. The pathogenesis of celiac disease. Gastroenterology 1998; 115: 206 – 10.
  • 24
    Stuber E, Buschenfeld A, Von Freier A, Arendt T, Folsch UR. Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL–Fas interaction: effect of pentoxifylline on the development of mucosal atrophy. Gut 1999; 45: 229 – 35.
  • 25
    Moss SF, Attia L, Scholes JV, Walters JR, Holt PR. Increased small intestinal apoptosis in coeliac disease. Gut 1996; 39: 811 – 7.
  • 26
    Soykan I, Ertan C, Ozden A. Severe anaphylactic reaction to infliximab: report of a case [letter]. Am J Gastroenterol 2000; 95: 2395 – 6.
    Direct Link:
  • 27
    Van Dullemen HM, Van Deventer SJ, Hommes DW, et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129 – 35.
View Full Article (HTML) Get PDF (149K)